此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Dinutuximab 联合化疗、手术和干细胞移植治疗新诊断的高危神经母细胞瘤儿童

2026年10月29日 更新者:National Cancer Institute (NCI)

Dinutuximab 添加到新诊断高危神经母细胞瘤儿童强化多模式治疗中的 3 期研究

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.

SECONDARY OBJECTIVES:

I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.

II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.

III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.

IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.

EXPLORATORY OBJECTIVES:

I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.

II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.

III. To compare patterns of failure between patients treated with and without dinutuximab during induction.

IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.

V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.

VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.

VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.

VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.

XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.

XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.

XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).

XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.

XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.

OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.

INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.

ARM A:

INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.

EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.

CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.

POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.

Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.

ARM B:

INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.

EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.

CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.

POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.

Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.

After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.

研究类型

介入性

注册 (估计的)

478

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Québec、加拿大、G1V 4G2
        • 招聘中
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
        • 首席研究员:
          • Bruno Michon
        • 接触:
    • Alberta
      • Calgary、Alberta、加拿大、T3B 6A8
        • 招聘中
        • Alberta Children's Hospital
        • 接触:
        • 首席研究员:
          • Victor A. Lewis
      • Edmonton、Alberta、加拿大、T6G 2B7
        • 招聘中
        • University of Alberta Hospital
        • 接触:
        • 首席研究员:
          • Sarah J. McKillop
    • British Columbia
      • Vancouver、British Columbia、加拿大、V6H 3V4
        • 招聘中
        • British Columbia Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:6477 604-875-2345
        • 首席研究员:
          • Rebecca J. Deyell
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R3E 0V9
        • 招聘中
        • CancerCare Manitoba
        • 接触:
        • 首席研究员:
          • Stephanie M. Villeneuve
    • Newfoundland and Labrador
      • St. John's、Newfoundland and Labrador、加拿大、A1B 3V6
        • 招聘中
        • Janeway Child Health Centre
        • 首席研究员:
          • Lisa A. Goodyear
        • 接触:
    • Nova Scotia
      • Halifax、Nova Scotia、加拿大、B3K 6R8
        • 招聘中
        • IWK Health Centre
        • 接触:
        • 首席研究员:
          • Chelsea Ash
    • Ontario
      • Hamilton、Ontario、加拿大、L8N 3Z5
        • 招聘中
        • McMaster Children's Hospital at Hamilton Health Sciences
        • 接触:
          • Site Public Contact
          • 电话号码:905-521-2100
        • 首席研究员:
          • Uma H. Athale
      • London、Ontario、加拿大、N6A 5W9
        • 招聘中
        • Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:519-685-8306
        • 首席研究员:
          • Shayna M. Zelcer
      • Ottawa、Ontario、加拿大、K1H 8L1
        • 招聘中
        • Children's Hospital of Eastern Ontario
        • 接触:
          • Site Public Contact
          • 电话号码:613-737-7600
        • 首席研究员:
          • Donna L. Johnston
      • Toronto、Ontario、加拿大、M5G 1X8
        • 招聘中
        • Hospital for Sick Children
        • 接触:
        • 首席研究员:
          • Daniel A. Morgenstern
    • Quebec
      • Montreal、Quebec、加拿大、H3H 1P3
        • 招聘中
        • The Montreal Children's Hospital of the MUHC
        • 接触:
        • 首席研究员:
          • Stephanie Mourad
      • Montreal、Quebec、加拿大、H3T 1C5
        • 招聘中
        • Centre Hospitalier Universitaire Sainte-Justine
        • 首席研究员:
          • Monia Marzouki
        • 接触:
      • Sherbrooke、Quebec、加拿大、J1H 5N4
        • 招聘中
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • 接触:
        • 首席研究员:
          • Stephanie Vairy
    • Saskatchewan
      • Saskatoon、Saskatchewan、加拿大、S7N 0W8
    • Auckland
      • Grafton、Auckland、新西兰、1145
        • 招聘中
        • Starship Children's Hospital
        • 首席研究员:
          • Andrew C. Wood
        • 接触:
          • Site Public Contact
          • 电话号码:0800 728 436
      • San Juan、波多黎各、00926
        • 招聘中
        • University Pediatric Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:787-474-0333
        • 首席研究员:
          • Maria E. Echevarria
    • New South Wales
      • Randwick、New South Wales、澳大利亚、2031
        • 招聘中
        • Sydney Children's Hospital
        • 首席研究员:
          • Draga Barbaric
        • 接触:
          • Site Public Contact
          • 电话号码:(02) 9382-1721
      • Westmead、New South Wales、澳大利亚、2145
        • 招聘中
        • The Children's Hospital at Westmead
        • 接触:
          • Site Public Contact
          • 电话号码:61-2-9845 1400
        • 首席研究员:
          • Bhavna Padhye
    • Queensland
      • South Brisbane、Queensland、澳大利亚、4101
        • 招聘中
        • Queensland Children's Hospital
        • 首席研究员:
          • Steven A. Foresto
        • 接触:
          • Site Public Contact
          • 电话号码:61 7 3068 1111
    • Victoria
      • Parkville、Victoria、澳大利亚、3052
        • 招聘中
        • Royal Children's Hospital
        • 首席研究员:
          • Martin A. Campbell
        • 接触:
    • Western Australia
      • Perth、Western Australia、澳大利亚、6009
    • Alabama
      • Birmingham、Alabama、美国、35233
        • 招聘中
        • Children's Hospital of Alabama
        • 接触:
        • 首席研究员:
          • Elizabeth D. Alva
      • Mobile、Alabama、美国、36604
        • 招聘中
        • USA Health Strada Patient Care Center
        • 接触:
          • Site Public Contact
          • 电话号码:800-388-8721
        • 首席研究员:
          • Hamayun Imran
    • Arizona
      • Mesa、Arizona、美国、85202
        • 招聘中
        • Banner Children's at Desert
        • 接触:
          • Site Public Contact
          • 电话号码:480-412-3100
        • 首席研究员:
          • Joseph C. Torkildson
      • Phoenix、Arizona、美国、85016
        • 招聘中
        • Phoenix Childrens Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:602-546-0920
        • 首席研究员:
          • Alok K. Kothari
      • Tucson、Arizona、美国、85719
        • 招聘中
        • Banner University Medical Center - Tucson
        • 接触:
        • 首席研究员:
          • Monica M. Davini
    • Arkansas
      • Little Rock、Arkansas、美国、72202-3591
        • 招聘中
        • Arkansas Children's Hospital
        • 首席研究员:
          • Michael W. Bishop
        • 接触:
          • Site Public Contact
          • 电话号码:501-364-7373
    • California
      • Downey、California、美国、90242
        • 招聘中
        • Kaiser Permanente Downey Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:626-564-3455
        • 首席研究员:
          • Robert M. Cooper
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope Comprehensive Cancer Center
        • 接触:
        • 首席研究员:
          • Hung C. Tran
      • Loma Linda、California、美国、92354
        • 招聘中
        • Loma Linda University Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:909-558-4050
        • 首席研究员:
          • Albert Kheradpour
      • Long Beach、California、美国、90806
        • 招聘中
        • Miller Children's and Women's Hospital Long Beach
        • 接触:
          • Site Public Contact
          • 电话号码:562-933-5600
        • 首席研究员:
          • Jacqueline N. Casillas
      • Los Angeles、California、美国、90027
        • 招聘中
        • Children's Hospital Los Angeles
        • 接触:
          • Site Public Contact
          • 电话号码:323-361-4110
        • 首席研究员:
          • Araz Marachelian
      • Los Angeles、California、美国、90048
        • 招聘中
        • Cedars-Sinai Medical Center
        • 首席研究员:
          • Fataneh (Fae) Majlessipour
        • 接触:
      • Los Angeles、California、美国、90095
        • 招聘中
        • Mattel Children's Hospital UCLA
        • 接触:
          • Site Public Contact
          • 电话号码:310-825-6708
        • 首席研究员:
          • Satiro N. De Oliveira
      • Madera、California、美国、93636
        • 招聘中
        • Valley Children's Hospital
        • 接触:
        • 首席研究员:
          • Ruetima Titapiwatanakun
      • Oakland、California、美国、94611
        • 招聘中
        • Kaiser Permanente-Oakland
        • 接触:
          • Site Public Contact
          • 电话号码:877-642-4691
          • 邮箱:Kpoct@kp.org
        • 首席研究员:
          • Aarati V. Rao
      • Oakland、California、美国、94609
        • 招聘中
        • UCSF Benioff Children's Hospital Oakland
        • 首席研究员:
          • Jennifer G. Michlitsch
        • 接触:
      • Orange、California、美国、92868
        • 招聘中
        • Children's Hospital of Orange County
        • 接触:
        • 首席研究员:
          • Elyssa M. Rubin
      • Palo Alto、California、美国、94304
        • 招聘中
        • Lucile Packard Children's Hospital Stanford University
        • 接触:
        • 首席研究员:
          • Jay Michael S. Balagtas
      • Sacramento、California、美国、95817
        • 招聘中
        • University of California Davis Comprehensive Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:916-734-3089
        • 首席研究员:
          • Marcio H. Malogolowkin
      • Sacramento、California、美国、95816
      • San Diego、California、美国、92123
        • 招聘中
        • Rady Children's Hospital - San Diego
        • 接触:
          • Site Public Contact
          • 电话号码:858-966-5934
        • 首席研究员:
          • William D. Roberts
      • San Francisco、California、美国、94158
        • 招聘中
        • UCSF Medical Center-Mission Bay
        • 接触:
        • 首席研究员:
          • Arun A. Rangaswami
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • Children's Hospital Colorado
        • 首席研究员:
          • Navin R. Pinto
        • 接触:
    • Connecticut
      • Hartford、Connecticut、美国、06106
        • 招聘中
        • Connecticut Children's Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:860-545-9981
        • 首席研究员:
          • Michael S. Isakoff
      • New Haven、Connecticut、美国、06520
        • 招聘中
        • Yale University
        • 接触:
        • 首席研究员:
          • Farzana Pashankar
    • Delaware
      • Wilmington、Delaware、美国、19803
        • 招聘中
        • Alfred I duPont Hospital for Children
        • 接触:
        • 首席研究员:
          • Sridhi Patel
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • 招聘中
        • Children's National Medical Center
        • 首席研究员:
          • Jeffrey S. Dome
        • 接触:
    • Florida
      • Fort Lauderdale、Florida、美国、33316
        • 招聘中
        • Broward Health Medical Center
        • 接触:
        • 首席研究员:
          • Hector M. Rodriguez-Cortes
      • Fort Myers、Florida、美国、33908
        • 招聘中
        • Golisano Children's Hospital of Southwest Florida
        • 接触:
        • 首席研究员:
          • Emad K. Salman
      • Gainesville、Florida、美国、32610
        • 招聘中
        • UF Health Cancer Institute - Gainesville
        • 接触:
        • 首席研究员:
          • Brian Stover
      • Hollywood、Florida、美国、33021
        • 招聘中
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:954-265-1847
          • 邮箱:OHR@mhs.net
        • 首席研究员:
          • Iftikhar Hanif
      • Jacksonville、Florida、美国、32207
        • 招聘中
        • Nemours Children's Clinic-Jacksonville
        • 接触:
        • 首席研究员:
          • Sridhi Patel
      • Miami、Florida、美国、33155
        • 招聘中
        • Nicklaus Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:888-624-2778
        • 首席研究员:
          • Ziad A. Khatib
      • Miami、Florida、美国、33136
        • 招聘中
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:305-243-2647
        • 首席研究员:
          • Meghan McCormick
      • Orlando、Florida、美国、32806
        • 招聘中
        • Arnold Palmer Hospital for Children
        • 接触:
        • 首席研究员:
          • Zhongbo Hu
      • Orlando、Florida、美国、32827
        • 招聘中
        • Nemours Children's Hospital
        • 接触:
        • 首席研究员:
          • Sridhi Patel
      • Orlando、Florida、美国、32803
        • 招聘中
        • AdventHealth Orlando
        • 接触:
        • 首席研究员:
          • Fouad M. Hajjar
      • St. Petersburg、Florida、美国、33701
        • 招聘中
        • Johns Hopkins All Children's Hospital
        • 接触:
        • 首席研究员:
          • Jennifer B. Dean
      • West Palm Beach、Florida、美国、33407
        • 招聘中
        • Saint Mary's Medical Center
        • 首席研究员:
          • Matthew D. Ramirez
        • 接触:
          • Site Public Contact
          • 电话号码:561-822-4745
    • Georgia
      • Atlanta、Georgia、美国、30329
        • 招聘中
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • 首席研究员:
          • William T. Cash
        • 接触:
      • Savannah、Georgia、美国、31404
        • 招聘中
        • Memorial Health University Medical Center
        • 接触:
        • 首席研究员:
          • James N. Yarnall
    • Hawaii
      • Honolulu、Hawaii、美国、96826
        • 招聘中
        • Kapiolani Medical Center for Women and Children
        • 接触:
          • Site Public Contact
          • 电话号码:808-983-6090
        • 首席研究员:
          • Wade T. Kyono
    • Illinois
      • Chicago、Illinois、美国、60611
        • 招聘中
        • Lurie Children's Hospital-Chicago
        • 接触:
          • Site Public Contact
          • 电话号码:773-880-4562
        • 首席研究员:
          • Elizabeth A. Sokol
      • Chicago、Illinois、美国、60637
        • 招聘中
        • University of Chicago Comprehensive Cancer Center
        • 接触:
        • 首席研究员:
          • Ami V. Desai
      • Chicago、Illinois、美国、60612
        • 招聘中
        • University of Illinois
        • 接触:
          • Site Public Contact
          • 电话号码:312-355-3046
        • 首席研究员:
          • Dipti S. Dighe
      • Oak Lawn、Illinois、美国、60453
        • 招聘中
        • Advocate Children's Hospital-Oak Lawn
        • 接触:
          • Site Public Contact
          • 电话号码:847-723-7570
        • 首席研究员:
          • Rebecca E. McFall
      • Park Ridge、Illinois、美国、60068
      • Peoria、Illinois、美国、61637
      • Springfield、Illinois、美国、62702
        • 招聘中
        • Southern Illinois University School of Medicine
        • 接触:
          • Site Public Contact
          • 电话号码:217-545-7929
        • 首席研究员:
          • Gregory P. Brandt
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • 招聘中
        • Riley Hospital for Children
        • 接触:
          • Site Public Contact
          • 电话号码:800-248-1199
        • 首席研究员:
          • Marissa Just
      • Indianapolis、Indiana、美国、46260
        • 招聘中
        • Ascension Saint Vincent Indianapolis Hospital
        • 接触:
        • 首席研究员:
          • Bassem I. Razzouk
    • Iowa
      • Des Moines、Iowa、美国、50309
        • 招聘中
        • Blank Children's Hospital
        • 接触:
        • 首席研究员:
          • Samantha L. Mallory
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • University of Iowa/Holden Comprehensive Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:800-237-1225
        • 首席研究员:
          • Andrew P. Groves
    • Kansas
      • Wichita、Kansas、美国、67214
        • 招聘中
        • Wesley Medical Center
        • 接触:
        • 首席研究员:
          • Nathan S. Hall
    • Kentucky
      • Lexington、Kentucky、美国、40536
        • 招聘中
        • University of Kentucky/Markey Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:859-257-3379
        • 首席研究员:
          • James T. Badgett
      • Louisville、Kentucky、美国、40202
        • 招聘中
        • Norton Children's Hospital
        • 接触:
        • 首席研究员:
          • Michael J. Ferguson
    • Louisiana
      • New Orleans、Louisiana、美国、70118
        • 招聘中
        • Children's Hospital New Orleans
        • 首席研究员:
          • Maria C. Velez-Yanguas
        • 接触:
          • Site Public Contact
          • 电话号码:504-894-5377
    • Maine
      • Bangor、Maine、美国、04401
        • 招聘中
        • Eastern Maine Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:207-973-4274
        • 首席研究员:
          • Daniel L. Callaway
      • Scarborough、Maine、美国、04074
        • 招聘中
        • Maine Children's Cancer Program
        • 首席研究员:
          • Sei-Gyung K. Sze
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • 首席研究员:
          • Allen R. Chen
        • 接触:
      • Baltimore、Maryland、美国、21215
        • 招聘中
        • Sinai Hospital of Baltimore
        • 首席研究员:
          • Jason M. Fixler
        • 接触:
          • Site Public Contact
          • 电话号码:410-601-9083
      • Baltimore、Maryland、美国、21201
        • 招聘中
        • University of Maryland/Greenebaum Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:800-888-8823
        • 首席研究员:
          • Teresa A. York
      • Bethesda、Maryland、美国、20889-5600
        • 招聘中
        • Walter Reed National Military Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:301-319-2100
        • 首席研究员:
          • Kip R. Hartman
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:877-726-5130
        • 首席研究员:
          • Lauren H. Boal
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Dana-Farber Cancer Institute
        • 接触:
          • Site Public Contact
          • 电话号码:877-442-3324
        • 首席研究员:
          • Suzanne Shusterman
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • C S Mott Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:800-865-1125
        • 首席研究员:
          • Rajen Mody
      • Detroit、Michigan、美国、48201
        • 暂停
        • Children's Hospital of Michigan
      • Grand Rapids、Michigan、美国、49503
        • 招聘中
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • 接触:
        • 首席研究员:
          • Kathleen Y. Butler
      • Kalamazoo、Michigan、美国、49007
        • 招聘中
        • Bronson Methodist Hospital
        • 接触:
        • 首席研究员:
          • Kathleen Y. Butler
      • Royal Oak、Michigan、美国、48073
        • 招聘中
        • Corewell Health Children's
        • 接触:
          • Site Public Contact
          • 电话号码:248-551-7695
        • 首席研究员:
          • Marie V. Nelson
    • Minnesota
      • Minneapolis、Minnesota、美国、55404
        • 招聘中
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
        • 首席研究员:
          • Michael K. Richards
        • 接触:
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • University of Minnesota/Masonic Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:612-624-2620
        • 首席研究员:
          • Robin L. Williams
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic in Rochester
        • 接触:
          • Site Public Contact
          • 电话号码:855-776-0015
        • 首席研究员:
          • Peter Schoettler
    • Mississippi
      • Jackson、Mississippi、美国、39216
        • 招聘中
        • University of Mississippi Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:601-815-6700
        • 首席研究员:
          • Amanda Strobel
    • Missouri
      • Columbia、Missouri、美国、65212
        • 招聘中
        • University of Missouri Children's Hospital
        • 首席研究员:
          • Barbara A. Gruner
        • 接触:
      • Kansas City、Missouri、美国、64108
        • 招聘中
        • Children's Mercy Hospitals and Clinics
        • 首席研究员:
          • Keith J. August
        • 接触:
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University School of Medicine
        • 接触:
        • 首席研究员:
          • Frederick S. Huang
      • St Louis、Missouri、美国、63141
        • 招聘中
        • Mercy Hospital Saint Louis
        • 接触:
          • Site Public Contact
          • 电话号码:314-251-7066
        • 首席研究员:
          • Robin D. Hanson
    • Nebraska
      • Omaha、Nebraska、美国、68114
        • 招聘中
        • Children's Hospital and Medical Center of Omaha
        • 接触:
          • Site Public Contact
          • 电话号码:402-955-3949
        • 首席研究员:
          • Jill C. Beck
      • Omaha、Nebraska、美国、68198
        • 招聘中
        • University of Nebraska Medical Center
        • 接触:
        • 首席研究员:
          • Jill C. Beck
    • Nevada
      • Las Vegas、Nevada、美国、89135
        • 招聘中
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
        • 接触:
        • 首席研究员:
          • Joseph L. Lasky
    • New Hampshire
      • Lebanon、New Hampshire、美国、03756
        • 招聘中
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • 首席研究员:
          • Angela Ricci
        • 接触:
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • Hackensack University Medical Center
        • 首席研究员:
          • Katharine Offer
        • 接触:
          • Site Public Contact
          • 电话号码:551-996-2897
      • Morristown、New Jersey、美国、07960
        • 招聘中
        • Morristown Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:973-971-5900
        • 首席研究员:
          • Kathryn L. Laurie
      • New Brunswick、New Jersey、美国、08901
        • 招聘中
        • Saint Peter's University Hospital
        • 首席研究员:
          • Nibal A. Zaghloul
        • 接触:
      • New Brunswick、New Jersey、美国、08903
        • 招聘中
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:732-235-8675
        • 首席研究员:
          • Nehal S. Parikh
      • Newark、New Jersey、美国、07112
        • 招聘中
        • Newark Beth Israel Medical Center
        • 接触:
        • 首席研究员:
          • Teena Bhatla
      • Paterson、New Jersey、美国、07503
        • 招聘中
        • Saint Joseph's Regional Medical Center
        • 接触:
        • 首席研究员:
          • Alissa Kahn
    • New Mexico
      • Albuquerque、New Mexico、美国、87106
        • 暂停
        • University of New Mexico Cancer Center
    • New York
      • Albany、New York、美国、12208
        • 招聘中
        • Albany Medical Center
        • 接触:
          • Site Public Contact
          • 电话号码:518-262-5513
        • 首席研究员:
          • Lauren R. Weintraub
      • Buffalo、New York、美国、14263
        • 招聘中
        • Roswell Park Cancer Institute
        • 接触:
        • 首席研究员:
          • Clare J. Twist
      • Mineola、New York、美国、11501
        • 招聘中
        • NYU Langone Hospital - Long Island
        • 接触:
        • 首席研究员:
          • Chana L. Glasser
      • New Hyde Park、New York、美国、11040
        • 招聘中
        • The Steven and Alexandra Cohen Children's Medical Center of New York
        • 接触:
          • Site Public Contact
          • 电话号码:718-470-3460
        • 首席研究员:
          • Julie I. Krystal
      • New York、New York、美国、10032
        • 招聘中
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • 首席研究员:
          • Nobuko Hijiya
        • 接触:
      • New York、New York、美国、10016
        • 招聘中
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • 首席研究员:
          • Elizabeth A. Raetz
        • 接触:
      • Rochester、New York、美国、14642
        • 招聘中
        • University of Rochester
        • 接触:
          • Site Public Contact
          • 电话号码:585-275-5830
        • 首席研究员:
          • Rafi R. Kazi
      • Syracuse、New York、美国、13210
        • 招聘中
        • State University of New York Upstate Medical University
        • 接触:
          • Site Public Contact
          • 电话号码:315-464-5476
        • 首席研究员:
          • Melanie A. Comito
      • The Bronx、New York、美国、10467
        • 招聘中
        • Montefiore Medical Center - Moses Campus
        • 接触:
        • 首席研究员:
          • Alice Lee
      • Valhalla、New York、美国、10595
        • 招聘中
        • New York Medical College
        • 接触:
          • Site Public Contact
          • 电话号码:914-594-3794
        • 首席研究员:
          • Andrew J. Bellantoni
    • North Carolina
      • Asheville、North Carolina、美国、28801
      • Chapel Hill、North Carolina、美国、27599
        • 招聘中
        • UNC Lineberger Comprehensive Cancer Center
        • 接触:
        • 首席研究员:
          • Thomas B. Alexander
      • Charlotte、North Carolina、美国、28203
        • 招聘中
        • Carolinas Medical Center/Levine Cancer Institute
        • 接触:
          • Site Public Contact
          • 电话号码:800-804-9376
        • 首席研究员:
          • Joel A. Kaplan
      • Charlotte、North Carolina、美国、28204
        • 招聘中
        • Novant Health Presbyterian Medical Center
        • 接触:
        • 首席研究员:
          • Holly Edington
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University Medical Center
        • 首席研究员:
          • Jessica M. Sun
        • 接触:
          • Site Public Contact
          • 电话号码:888-275-3853
      • Greenville、North Carolina、美国、27834
        • 招聘中
        • East Carolina University
        • 接触:
        • 首席研究员:
          • Andrea R. Whitfield
      • Winston-Salem、North Carolina、美国、27157
        • 招聘中
        • Wake Forest University Health Sciences
        • 接触:
          • Site Public Contact
          • 电话号码:336-713-6771
        • 首席研究员:
          • Sarah Supples
    • North Dakota
      • Fargo、North Dakota、美国、58122
    • Ohio
      • Akron、Ohio、美国、44308
        • 招聘中
        • Children's Hospital Medical Center of Akron
        • 接触:
          • Site Public Contact
          • 电话号码:330-543-3193
        • 首席研究员:
          • Lauren R. Draper
      • Cincinnati、Ohio、美国、45229
        • 招聘中
        • Cincinnati Children's Hospital Medical Center
        • 接触:
        • 首席研究员:
          • Katherine M. Somers
      • Cleveland、Ohio、美国、44195
        • 招聘中
        • Cleveland Clinic Foundation
        • 接触:
        • 首席研究员:
          • Matteo M. Trucco
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • Rainbow Babies and Childrens Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:216-844-5437
        • 首席研究员:
          • Duncan S. Stearns
      • Columbus、Ohio、美国、43205
      • Dayton、Ohio、美国、45404
        • 招聘中
        • Dayton Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:800-228-4055
        • 首席研究员:
          • Jordan M. Wright
      • Toledo、Ohio、美国、43606
        • 招聘中
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
        • 接触:
        • 首席研究员:
          • Jamie L. Dargart
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • University of Oklahoma Health Sciences Center
        • 接触:
        • 首席研究员:
          • Rene Y. McNall-Knapp
      • Tulsa、Oklahoma、美国、74136
        • 招聘中
        • Saint Francis Children's Hospital
        • 首席研究员:
          • Jill A. Salo
        • 接触:
          • Site Public Contact
          • 电话号码:918-502-6720
    • Oregon
      • Portland、Oregon、美国、97227
        • 招聘中
        • Legacy Emanuel Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:503-413-2560
        • 首席研究员:
          • Jason M. Glover
      • Portland、Oregon、美国、97239
        • 招聘中
        • Oregon Health and Science University
        • 接触:
        • 首席研究员:
          • Susan J. Lindemulder
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18103
        • 招聘中
        • Lehigh Valley Hospital-Cedar Crest
        • 接触:
        • 首席研究员:
          • Jacob A. Troutman
      • Danville、Pennsylvania、美国、17822
        • 招聘中
        • Geisinger Medical Center
        • 首席研究员:
          • Jagadeesh Ramdas
        • 接触:
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Children's Hospital of Philadelphia
        • 首席研究员:
          • Rochelle Bagatell
        • 接触:
      • Philadelphia、Pennsylvania、美国、19134
        • 招聘中
        • Saint Christopher's Hospital for Children
        • 接触:
          • Site Public Contact
          • 电话号码:215-427-8991
        • 首席研究员:
          • Gregory E. Halligan
      • Pittsburgh、Pennsylvania、美国、15224
        • 招聘中
        • Children's Hospital of Pittsburgh of UPMC
        • 接触:
        • 首席研究员:
          • Jean M. Tersak
    • Rhode Island
      • Providence、Rhode Island、美国、02903
        • 招聘中
        • Rhode Island Hospital
        • 首席研究员:
          • Bradley DeNardo
        • 接触:
          • Site Public Contact
          • 电话号码:401-444-1488
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina
        • 接触:
        • 首席研究员:
          • Jacqueline M. Kraveka
      • Columbia、South Carolina、美国、29203
        • 招聘中
        • Prisma Health Richland Hospital
        • 首席研究员:
          • Stuart L. Cramer
        • 接触:
      • Greenville、South Carolina、美国、29605
        • 招聘中
        • BI-LO Charities Children's Cancer Center
        • 首席研究员:
          • Aniket Saha
        • 接触:
    • South Dakota
      • Sioux Falls、South Dakota、美国、57117-5134
    • Tennessee
      • Knoxville、Tennessee、美国、37916
        • 招聘中
        • East Tennessee Childrens Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:865-541-8266
        • 首席研究员:
          • Susan E. Spiller
      • Memphis、Tennessee、美国、38105
        • 招聘中
        • Saint Jude Children's Research Hospital
        • 首席研究员:
          • Sara M. Federico
        • 接触:
      • Nashville、Tennessee、美国、37232
        • 招聘中
        • Vanderbilt University/Ingram Cancer Center
        • 首席研究员:
          • Daniel J. Benedetti
        • 接触:
          • Site Public Contact
          • 电话号码:800-811-8480
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • The Children's Hospital at TriStar Centennial
        • 接触:
          • Site Public Contact
          • 电话号码:615-342-1919
        • 首席研究员:
          • Clinton M. Carroll
    • Texas
      • Austin、Texas、美国、78723
      • Corpus Christi、Texas、美国、78411
        • 招聘中
        • Driscoll Children's Hospital
        • 接触:
        • 首席研究员:
          • Nkechi I. Mba
      • Dallas、Texas、美国、75390
        • 招聘中
        • UT Southwestern/Simmons Cancer Center-Dallas
        • 首席研究员:
          • Tanya C. Watt
        • 接触:
      • Dallas、Texas、美国、75230
        • 招聘中
        • Medical City Dallas Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:972-566-5588
        • 首席研究员:
          • Maurizio L. Ghisoli
      • El Paso、Texas、美国、79905
        • 招聘中
        • El Paso Children's Hospital
        • 接触:
        • 首席研究员:
          • Benjamin Carcamo
      • Fort Worth、Texas、美国、76104
      • Houston、Texas、美国、77030
        • 招聘中
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • 接触:
          • Site Public Contact
          • 电话号码:713-798-1354
          • 邮箱:burton@bcm.edu
        • 首席研究员:
          • Jennifer H. Foster
      • Houston、Texas、美国、77030
        • 招聘中
        • UT MD Anderson Cancer Center
        • 接触:
        • 首席研究员:
          • Najat C. Daw
      • Lubbock、Texas、美国、79410
        • 招聘中
        • Covenant Children's Hospital
        • 首席研究员:
          • Kishor M. Bhende
        • 接触:
      • Lubbock、Texas、美国、79415
        • 招聘中
        • UMC Cancer Center / UMC Health System
        • 接触:
          • Site Public Contact
          • 电话号码:806-775-8590
        • 首席研究员:
          • Erin K. Barr
      • San Antonio、Texas、美国、78207
        • 招聘中
        • Children's Hospital of San Antonio
        • 接触:
        • 首席研究员:
          • Julie Voeller
      • San Antonio、Texas、美国、78229
        • 招聘中
        • University of Texas Health Science Center at San Antonio
        • 接触:
        • 首席研究员:
          • Aaron J. Sugalski
      • San Antonio、Texas、美国、78229
        • 招聘中
        • Methodist Children's Hospital of South Texas
        • 接触:
        • 首席研究员:
          • Jose M. Esquilin
    • Utah
      • Salt Lake City、Utah、美国、84113
        • 招聘中
        • Primary Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:801-585-5270
        • 首席研究员:
          • Leonora R. Slatnick
    • Vermont
      • Burlington、Vermont、美国、05405
        • 招聘中
        • University of Vermont and State Agricultural College
        • 接触:
          • Site Public Contact
          • 电话号码:802-656-8990
          • 邮箱:rpo@uvm.edu
        • 首席研究员:
          • Jessica L. Heath
    • Virginia
      • Charlottesville、Virginia、美国、22908
      • Portsmouth、Virginia、美国、23708-2197
        • 招聘中
        • Naval Medical Center - Portsmouth
        • 接触:
          • Site Public Contact
          • 电话号码:757-953-5939
        • 首席研究员:
          • Karin Brockman
    • Washington
      • Seattle、Washington、美国、98105
        • 招聘中
        • Seattle Children's Hospital
        • 接触:
          • Site Public Contact
          • 电话号码:866-987-2000
        • 首席研究员:
          • Sarah E. Leary
      • Spokane、Washington、美国、99204
        • 招聘中
        • Providence Sacred Heart Medical Center and Children's Hospital
        • 接触:
        • 首席研究员:
          • Judy L. Felgenhauer
      • Tacoma、Washington、美国、98405
        • 招聘中
        • Mary Bridge Children's Hospital and Health Center
        • 接触:
        • 首席研究员:
          • Robert G. Irwin
    • West Virginia
      • Huntington、West Virginia、美国、25701
        • 招聘中
        • Edwards Comprehensive Cancer Center
        • 首席研究员:
          • Mark A. Ranalli
        • 接触:
      • Morgantown、West Virginia、美国、26506
        • 招聘中
        • West Virginia University Healthcare
        • 接触:
        • 首席研究员:
          • Ashley E. Meyer
    • Wisconsin
      • Green Bay、Wisconsin、美国、54301
        • 暂停
        • Saint Vincent Hospital Cancer Center Green Bay
      • Madison、Wisconsin、美国、53792
        • 招聘中
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • 接触:
        • 首席研究员:
          • Margo L. Hoover-Regan
      • Marshfield、Wisconsin、美国、54449
      • Milwaukee、Wisconsin、美国、53226
        • 招聘中
        • Children's Hospital of Wisconsin
        • 首席研究员:
          • Angela Steineck
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 30年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131

  • ≤ 30 years at the time of initial diagnosis with high-risk disease

  • * Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines

    • Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:

      • Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
      • Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
      • Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
      • Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
  • Patients must have a body surface area (BSA) ≥ 0.25 m^2

  • No prior anti-cancer therapy except as outlined below:

    • Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
    • Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
    • Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
  • Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • A serum creatinine based on age/sex as follows:

    • 1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL

    • 6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL

    • 1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL

    • 2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL

    • 6 to < 10 years: Male 1 mg/dL and female 1 mg/dL

    • 10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL

    • 13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL

    • ≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL

      • The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
    • or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or

    • or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)

      • Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age

  • Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • * Shortening fraction of ≥ 27% by echocardiogram, or

    • Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
  • Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:

No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure

Exclusion Criteria:

  • Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
  • Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
  • Patients with known bone marrow failure syndromes
  • Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
  • Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
  • Lactating females who plan to breastfeed their infants
  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Arm A (SOC treatment)

See detailed description

Given IV

其他名称:
  • 芽生威
  • 卡宝
  • 卡铂六醇
  • 卡铂
  • 卡布辛
  • 卡波索尔
  • 卡博泰克
  • CBDCA
  • 迪普拉塔
  • 埃卡尔
  • JM-8
  • 内洛林
  • 新铂金
  • 副铂
  • 副铂 AQ
  • 对铂
  • 铂金瓦斯
  • 核糖体
  • JM8

Given IV

其他名称:
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦,2-[双(2-氯乙基)氨基]四氢-,2-氧化物,一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719
  • 阿斯塔B 518
  • B-518
  • WR-138719
  • 乙518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

其他名称:
  • CDDP
  • 顺式二氨合二氯铂
  • 顺铂
  • 新铂
  • 铂醇
  • 阿比铂
  • Blastolem
  • 布铂
  • 顺式二氨二氯铂
  • 顺式二氨二氯铂 (II)
  • 顺式二氯胺铂 (II)
  • 顺铂二氯化胺
  • 顺铂II
  • 顺铂II二胺二氯化物
  • 胞铂
  • 胞磷胆素
  • 扁豆属
  • 民进党
  • 莱德铂
  • 金属铂
  • 佩龙氯化物
  • 佩龙盐
  • 普拉西斯
  • 塑化剂
  • 铂金
  • 铂菌素
  • Platiblastin-S
  • 铂金-AQ
  • Platinol-AQ VHA Plus
  • 铂氧生
  • 铂
  • 二氯化铂
  • 普拉蒂兰
  • 普拉汀
  • 柏拉图素

Undergo bone marrow biopsy

其他名称:
  • 骨髓活检
  • 活组织检查,骨髓

Given IV

其他名称:
  • 阿德里亚斯汀
  • 羟基道诺霉素
  • 羟基柔红霉素

Given IV

其他名称:
  • 录像机
  • 亮新碱
  • 长春新碱
  • 液晶电阻率

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo ECHO

其他名称:
  • 超声心动图
  • 欧共体

Undergo MUGA

其他名称:
  • 血池扫描
  • 平衡放射性核素血管造影
  • 门控血池成像
  • 穆加
  • 放射性核素脑室造影
  • 导航导航仪
  • 司马扫描
  • 同步多门采集扫描
  • 穆加扫描
  • 多门控采集扫描
  • 放射性核素脑室造影扫描
  • 门控心池扫描
  • RNV扫描

Undergo bone marrow aspiration

Given IV

其他名称:
  • 去甲基鬼臼毒素乙苷
  • EPEG
  • 拉斯特
  • 拓扑萨
  • 韦贝斯
  • 副总裁 16
  • 副总裁 16-213
  • VP-16
  • VP-16-213
  • VP16
  • 副总裁 16213
  • VP-16213
  • VP16213

Undergo CT scan

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Given IV

其他名称:
  • 苯丙胺
  • 拓扑替康内酯

Undergo radiation therapy

其他名称:
  • 癌症放疗
  • 能源类型
  • 照射
  • 辐照
  • 辐射
  • 放射治疗,NOS
  • 放疗
  • 转播
  • 治疗、放射
  • 能量类型

Undergo blood and urine sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Ancillary studies

Given IV

其他名称:
  • CB-3025
  • 左旋聚丙烯酰胺
  • L-肌溶酶
  • 丙氨酸氮芥
  • L-苯丙氨酸芥末
  • L-肌溶酶苯丙氨酸芥
  • L-肌赖氨酸
  • 苯丙胺
  • 苯丙氨酸芥末
  • 苯丙氨酸氮芥
  • 肌氯蛋白
  • 溶血酶
  • WR-19813
  • 注射用美法仑-肝输送系统

Given IV

Given IV

其他名称:
  • 铁粉属
  • 奥克替帕
  • 斯泰帕
  • TESPA
  • 特斯帕明
  • TSPA
  • 1,1',1''-Phosphinothioylidynetrisaziridine
  • 吉罗斯坦
  • N,N', N''-三亚乙基硫代磷酰胺
  • 茶胺
  • 硫泰帕
  • 硫磷酰胺
  • 硫菌灵
  • 硫代磷酰胺
  • 噻吩
  • 替福西林
  • 三聚氰胺
  • Tiotef
  • 三乙烯硫磷酰胺
  • 三乙烯硫代磷酰胺
  • 三(1-氮丙啶基)硫化膦
  • WR 45312
  • SH 105
  • SH-105
  • SH105
  • 特吡鲁特

Given IV

其他名称:
  • Ch14.18
  • 卡尔兹巴
  • 14.18UTC
  • 摩押 Ch14.18
  • 单克隆抗体 Ch14.18
  • 优妥昔单抗
  • Dinutuximab Beta

Undergo FDG PET

其他名称:
  • 葡萄糖PET/CT

Undergo stem cell infusion

其他名称:
  • HSCT
  • HCT
  • 造血干细胞移植
  • 干细胞移植
  • 造血干细胞输液
  • SCT
  • 干细胞移植,NOS

Given PO

其他名称:
  • 大赦
  • 肉桂烷
  • 克拉拉维斯
  • 索特雷
  • 13-顺视黄酸
  • 13-顺式视黄酸
  • 13-顺式维生素A酸
  • 13-cRA
  • 吸收剂
  • 准确的
  • 维甲酸
  • 顺维甲酸
  • 异维甲酸
  • 益生菌
  • 异曲霉素
  • 妙立山
  • 新维生素A
  • 新维生素A酸
  • 奥拉坦
  • 罗 4-3780
  • Ro-4-3780
  • 罗库坦
  • 泽纳坦

Undergo apheresis

其他名称:
  • 白细胞分离术
  • 治疗性白细胞分离术
  • 白细胞吸附分离术
  • 白细胞减少血浆分离术

Undergo I-MIBG scan

其他名称:
  • 纳米
  • 核医学
  • 核医学扫描
  • 放射成像
  • 放射性核素扫描
  • 扫描
  • 闪烁显像
  • 伽马扫描

Given PO or via NG or G tube

其他名称:
  • 特莫达尔
  • SCH 52365
  • 泰莫达
  • Temcad软件
  • 甲唑司酮
  • RP-46161
  • 特莫美达
  • TMZ
  • CCRG-81045
  • 咪唑并[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-
  • 并购 39831
  • M和B 39831
  • 格利奥特姆
  • 替咪唑

Undergo tumor resection surgery

实验性的:Arm B (Dinutuximab in induction)

See detailed description

Given IV

其他名称:
  • 芽生威
  • 卡宝
  • 卡铂六醇
  • 卡铂
  • 卡布辛
  • 卡波索尔
  • 卡博泰克
  • CBDCA
  • 迪普拉塔
  • 埃卡尔
  • JM-8
  • 内洛林
  • 新铂金
  • 副铂
  • 副铂 AQ
  • 对铂
  • 铂金瓦斯
  • 核糖体
  • JM8

Given IV

其他名称:
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦,2-[双(2-氯乙基)氨基]四氢-,2-氧化物,一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719
  • 阿斯塔B 518
  • B-518
  • WR-138719
  • 乙518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

其他名称:
  • CDDP
  • 顺式二氨合二氯铂
  • 顺铂
  • 新铂
  • 铂醇
  • 阿比铂
  • Blastolem
  • 布铂
  • 顺式二氨二氯铂
  • 顺式二氨二氯铂 (II)
  • 顺式二氯胺铂 (II)
  • 顺铂二氯化胺
  • 顺铂II
  • 顺铂II二胺二氯化物
  • 胞铂
  • 胞磷胆素
  • 扁豆属
  • 民进党
  • 莱德铂
  • 金属铂
  • 佩龙氯化物
  • 佩龙盐
  • 普拉西斯
  • 塑化剂
  • 铂金
  • 铂菌素
  • Platiblastin-S
  • 铂金-AQ
  • Platinol-AQ VHA Plus
  • 铂氧生
  • 铂
  • 二氯化铂
  • 普拉蒂兰
  • 普拉汀
  • 柏拉图素

Undergo bone marrow biopsy

其他名称:
  • 骨髓活检
  • 活组织检查,骨髓

Given IV

其他名称:
  • 阿德里亚斯汀
  • 羟基道诺霉素
  • 羟基柔红霉素

Given IV

其他名称:
  • 录像机
  • 亮新碱
  • 长春新碱
  • 液晶电阻率

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Undergo ECHO

其他名称:
  • 超声心动图
  • 欧共体

Undergo MUGA

其他名称:
  • 血池扫描
  • 平衡放射性核素血管造影
  • 门控血池成像
  • 穆加
  • 放射性核素脑室造影
  • 导航导航仪
  • 司马扫描
  • 同步多门采集扫描
  • 穆加扫描
  • 多门控采集扫描
  • 放射性核素脑室造影扫描
  • 门控心池扫描
  • RNV扫描

Undergo bone marrow aspiration

Given IV

其他名称:
  • 去甲基鬼臼毒素乙苷
  • EPEG
  • 拉斯特
  • 拓扑萨
  • 韦贝斯
  • 副总裁 16
  • 副总裁 16-213
  • VP-16
  • VP-16-213
  • VP16
  • 副总裁 16213
  • VP-16213
  • VP16213

Undergo CT scan

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Given IV

其他名称:
  • 苯丙胺
  • 拓扑替康内酯

Undergo radiation therapy

其他名称:
  • 癌症放疗
  • 能源类型
  • 照射
  • 辐照
  • 辐射
  • 放射治疗,NOS
  • 放疗
  • 转播
  • 治疗、放射
  • 能量类型

Undergo blood and urine sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Ancillary studies

Given IV

其他名称:
  • CB-3025
  • 左旋聚丙烯酰胺
  • L-肌溶酶
  • 丙氨酸氮芥
  • L-苯丙氨酸芥末
  • L-肌溶酶苯丙氨酸芥
  • L-肌赖氨酸
  • 苯丙胺
  • 苯丙氨酸芥末
  • 苯丙氨酸氮芥
  • 肌氯蛋白
  • 溶血酶
  • WR-19813
  • 注射用美法仑-肝输送系统

Given IV

Given IV

其他名称:
  • 铁粉属
  • 奥克替帕
  • 斯泰帕
  • TESPA
  • 特斯帕明
  • TSPA
  • 1,1',1''-Phosphinothioylidynetrisaziridine
  • 吉罗斯坦
  • N,N', N''-三亚乙基硫代磷酰胺
  • 茶胺
  • 硫泰帕
  • 硫磷酰胺
  • 硫菌灵
  • 硫代磷酰胺
  • 噻吩
  • 替福西林
  • 三聚氰胺
  • Tiotef
  • 三乙烯硫磷酰胺
  • 三乙烯硫代磷酰胺
  • 三(1-氮丙啶基)硫化膦
  • WR 45312
  • SH 105
  • SH-105
  • SH105
  • 特吡鲁特

Given IV

其他名称:
  • Ch14.18
  • 卡尔兹巴
  • 14.18UTC
  • 摩押 Ch14.18
  • 单克隆抗体 Ch14.18
  • 优妥昔单抗
  • Dinutuximab Beta

Undergo FDG PET

其他名称:
  • 葡萄糖PET/CT

Undergo stem cell infusion

其他名称:
  • HSCT
  • HCT
  • 造血干细胞移植
  • 干细胞移植
  • 造血干细胞输液
  • SCT
  • 干细胞移植,NOS

Given PO

其他名称:
  • 大赦
  • 肉桂烷
  • 克拉拉维斯
  • 索特雷
  • 13-顺视黄酸
  • 13-顺式视黄酸
  • 13-顺式维生素A酸
  • 13-cRA
  • 吸收剂
  • 准确的
  • 维甲酸
  • 顺维甲酸
  • 异维甲酸
  • 益生菌
  • 异曲霉素
  • 妙立山
  • 新维生素A
  • 新维生素A酸
  • 奥拉坦
  • 罗 4-3780
  • Ro-4-3780
  • 罗库坦
  • 泽纳坦

Undergo apheresis

其他名称:
  • 白细胞分离术
  • 治疗性白细胞分离术
  • 白细胞吸附分离术
  • 白细胞减少血浆分离术

Undergo I-MIBG scan

其他名称:
  • 纳米
  • 核医学
  • 核医学扫描
  • 放射成像
  • 放射性核素扫描
  • 扫描
  • 闪烁显像
  • 伽马扫描

Given PO or via NG or G tube

其他名称:
  • 特莫达尔
  • SCH 52365
  • 泰莫达
  • Temcad软件
  • 甲唑司酮
  • RP-46161
  • 特莫美达
  • TMZ
  • CCRG-81045
  • 咪唑并[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-
  • 并购 39831
  • M和B 39831
  • 格利奥特姆
  • 替咪唑

Undergo tumor resection surgery

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Event free survival (EFS)
大体时间:Up to 3 years

EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.

Up to 3 years

次要结果测量

结果测量
措施说明
大体时间
End of Induction (EOI) response rate
大体时间:From randomization to end of extended Induction, up to 12 months

The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC)

From randomization to end of extended Induction, up to 12 months
Overall survival (OS)
大体时间:Up to 3 years

OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive.

Up to 3 years
Incidence of adverse events
大体时间:Up to 2 years

The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported.

Up to 2 years
GD2 expression
大体时间:Up to 12 months

Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low.

Up to 12 months

其他结果措施

结果测量
措施说明
大体时间
Association between tumor and host factors and outcomes
大体时间:Up to 10 years

A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome.

Up to 10 years
Circulating biomarkers and markers of minimal residual disease
大体时间:Up to 10 years

Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate.

Up to 10 years
Patterns of failure
大体时间:Up to 10 years

The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test.

Up to 10 years
Effect of telomere maintenance mechanisms
大体时间:Up to 10 years

A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM.

Up to 10 years
Functional and quality of life outcomes
大体时间:At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy

Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A).

At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
Adequacy of diagnostic biopsy specimens
大体时间:At time of tissue collection

Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy.

At time of tissue collection
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
大体时间:Up to 10 years

Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored.

Up to 10 years
Develop and validate deep learning predictors of Induction response (imaging objective)
大体时间:At diagnosis, EOI, during Extended Induction, and end of Extended Induction

Scans will be given as input to a convolutional neural network trained to predict EOI response.

At diagnosis, EOI, during Extended Induction, and end of Extended Induction
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
大体时间:Up to 10 years

Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures.

Up to 10 years
Incidence of late toxicities
大体时间:Up to 10 years

Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion.

Up to 10 years
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
大体时间:Up to 10 years

The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test.

Up to 10 years
Post-transplant complications
大体时间:Up to 100 days post-transplant

Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed.

Up to 100 days post-transplant
Associations between end of induction (EOI) response and individual response components
大体时间:Up to 10 years

Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).

Up to 10 years
Changes in image-defined risk factors (IDRF)
大体时间:Up to 10 years

The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel.

Up to 10 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sara M Federico、Children's Oncology Group

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月19日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2029年12月31日

研究注册日期

首次提交

2023年12月13日

首先提交符合 QC 标准的

2023年12月13日

首次发布 (实际的)

2023年12月15日

研究记录更新

最后更新发布 (实际的)

2026年10月30日

上次提交的符合 QC 标准的更新

2026年10月29日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • NCI-2023-08530
  • U10CA180886 (美国 NIH 拨款/合同)
  • NCI-2023-08530 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • ANBL2131 (其他标识符:CTEP)
  • ANBL2131 (其他标识符:Children's Oncology Group)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅